Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Hepatology Communications
|
May 15, 2023
Evolution of systemic therapy for advanced HCC patients: Did we make progress in 2022?
Jeffrey Sum Lung Wong, Roland Leung, Tan To Cheung, et al.
Translational Gastroenterology and Hepatology
|
August 4, 2025
A step towards multimodality relief for painful hepatic cancer: the CCTG HE1 trial
Jeffrey Sum Lung Wong, Roland Leung, Bryan Cho Wing Li, et al.
The Lancet. Oncology
|
January 24, 2025
Insights into the future of first-line advanced hepatocellular carcinoma treatment
Jeffrey Sum Lung Wong, Carmen Chak-Lui Wong, Frances Sze Kei Sun, et al.
Cancers
|
May 4, 2026
Anti-Tumor Immunity in Solid-Organ Transplant Recipients
Jeffrey Sum Lung Wong, Karen Hoi Lam Li, Bryan Li, et al.
Expert Review of Gastroenterology & Hepatology
|
March 5, 2021
Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib
Josephine Tsang, Jeffrey Sum Lung Wong, Gerry Gin Wai Kwok, et al.
Liver Cancer
|
June 24, 2026
Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis
Frances Sze Kei Sun, Jeffrey Sum Lung Wong, Lung-Yi Mak, et al.
Journal of the National Cancer Institute
|
March 15, 2022
Increased CD8+ T-cell Infiltration and Efficacy for Multikinase Inhibitors After PD-1 Blockade in Hepatocellular Carcinoma
Hiroto Kikuchi, Aya Matsui, Satoru Morita, et al.
Cancers
|
April 30, 2021
Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC
Yawen Dong, Jeffrey Sum Lung Wong, Ryohichi Sugimura, et al.
Journal for Immunotherapy of Cancer
|
February 10, 2021
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
Jeffrey Sum Lung Wong, Gerry Gin Wai Kwok, Vikki Tang, et al.
Liver Cancer
|
May 29, 2026
Efficacy of Nivolumab plus Ipilimumab in Advanced Hepatocellular Carcinoma with and without High-Risk Features: An International Multicenter Study
Jung Sun Kim, San-Chi Chen, Jeffrey Sum Lung Wong, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Hepatology Communications
|
May 15, 2023
Evolution of systemic therapy for advanced HCC patients: Did we make progress in 2022?
Jeffrey Sum Lung Wong, Roland Leung, Tan To Cheung, et al.
Translational Gastroenterology and Hepatology
|
August 4, 2025
A step towards multimodality relief for painful hepatic cancer: the CCTG HE1 trial
Jeffrey Sum Lung Wong, Roland Leung, Bryan Cho Wing Li, et al.
The Lancet. Oncology
|
January 24, 2025
Insights into the future of first-line advanced hepatocellular carcinoma treatment
Jeffrey Sum Lung Wong, Carmen Chak-Lui Wong, Frances Sze Kei Sun, et al.
Cancers
|
May 4, 2026
Anti-Tumor Immunity in Solid-Organ Transplant Recipients
Jeffrey Sum Lung Wong, Karen Hoi Lam Li, Bryan Li, et al.
Expert Review of Gastroenterology & Hepatology
|
March 5, 2021
Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib
Josephine Tsang, Jeffrey Sum Lung Wong, Gerry Gin Wai Kwok, et al.
Liver Cancer
|
June 24, 2026
Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis
Frances Sze Kei Sun, Jeffrey Sum Lung Wong, Lung-Yi Mak, et al.
Journal of the National Cancer Institute
|
March 15, 2022
Increased CD8+ T-cell Infiltration and Efficacy for Multikinase Inhibitors After PD-1 Blockade in Hepatocellular Carcinoma
Hiroto Kikuchi, Aya Matsui, Satoru Morita, et al.
Cancers
|
April 30, 2021
Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC
Yawen Dong, Jeffrey Sum Lung Wong, Ryohichi Sugimura, et al.
Journal for Immunotherapy of Cancer
|
February 10, 2021
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
Jeffrey Sum Lung Wong, Gerry Gin Wai Kwok, Vikki Tang, et al.
Liver Cancer
|
May 29, 2026
Efficacy of Nivolumab plus Ipilimumab in Advanced Hepatocellular Carcinoma with and without High-Risk Features: An International Multicenter Study
Jung Sun Kim, San-Chi Chen, Jeffrey Sum Lung Wong, et al.
Page
of 2